Lilly cuts Zepbound self-pay pricing to $299–$449
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.
All-in monthly cost at 10 mg
Self-pay vial pricing effective 23 February 2026 runs $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above, conditional on refilling within 45 days of the previous delivery.
Miss that window and the standard self-pay price applies for that refill, which turns a predictable brand price into an unpredictable one if a delivery slips.
At the starter dose this is competitive with several compounded programmes; at maintenance it remains roughly double the cheapest verified compounded route.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.